The9 Expands into Biopharmaceuticals with NYB Merger for Innovative Drug Discovery

The9's Strategic Move into Biopharmaceuticals through NYB Merger

The9 Limited's investee company, Nanyang Biologics Pte. Ltd. (NYB), is set to become a publicly traded entity following a business combination agreement with RF Acquisition Corp II. The transaction, which carries an expected pre-transaction equity valuation of approximately $1.5 billion, has received board approvals from both parties and is anticipated to finalize in the first or second quarter of 2026, pending shareholder endorsement and customary closing conditions. This significant merger underscores The9's commitment to expanding its footprint in the biopharmaceutical sector, particularly in the area of drug discovery.

NYB aims to revolutionize drug discovery processes by leveraging its artificial intelligence (AI) platform to identify effective drug molecules and natural ingredients. This innovative approach not only positions NYB at the forefront of modern pharmaceutical development but also aligns with global trends towards integrating AI in healthcare. The recent recognition of NYB winning the 1st Prize at the SuperAI Genesis Startup Competition 2025 highlights the company's strong potential and competitive edge. The achievement signals robust interest and confidence in NYB's capabilities within a crowded market.

Moreover, NYB's collaboration with tech giants such as Nvidia, Hewlett Packard Enterprise, and Equinix aims to construct the world’s largest natural compound library and develop scalable AI platforms for drug discovery. This partnership emphasizes the need for secure digital infrastructure to safeguard sensitive scientific data, particularly in biopharmaceutical development. The combination of NYB’s growing portfolio of patents and its strategic partnerships sets the stage for groundbreaking innovations in therapeutic solutions, positioning the company for success post-merger.

In addition to these developments, NYB is poised to structure its board with a majority designated for the combined entity, ensuring that existing stakeholders, including The9, maintain a significant stake. This strategic governance structure aims to foster continuity and stability as NYB transitions into its new phase as a publicly listed company, enhancing its ability to navigate the complexities of the biopharmaceutical landscape.

As NYB moves forward, its focus on developing first-in-class therapeutic solutions and expanding its drug-candidate pipeline remains a priority. The anticipated merger not only enhances The9’s investment portfolio but also reflects the growing intersection of technology and healthcare in the quest for innovative medical solutions.